Form 4: Ventyx Biosciences CEO Reports Stock Transaction

CEO Raju Mohan reports the vesting of restricted stock units resulting in the acquisition of 11,844 shares of Ventyx Biosciences common stock.

Summary

• On March 28, 2025, Raju Mohan, CEO and President of Ventyx Biosciences, Inc., reported a transaction involving restricted stock units.
• The transaction involved the vesting of 11,844 restricted stock units, each representing a contingent right to receive one share of Ventyx Biosciences common stock.
• This resulted in Mr. Mohan acquiring 11,844 shares of common stock at a price of $0 per share.
• Following the transaction, Mr. Mohan directly owns 2,303,540 shares of Ventyx Biosciences common stock and 23,688 restricted stock units.
• The restricted stock units vest over four years, with 25% vesting annually starting on the one-year anniversary of March 28, 2023, subject to continued service.

Sentiment

Score: 5

Explanation: This is a neutral event. It's a standard reporting of stock transactions by an insider, reflecting compensation rather than a strategic shift.

Positives

• The vesting of restricted stock units indicates that the CEO is meeting the conditions of their compensation package.
• The CEO's increased stake in the company could align their interests with those of shareholders.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects the CEO's compensation and alignment with company performance.

Key Dates

Keywords

Ventyx Biosciences, Raju Mohan, CEO, restricted stock units, stock transaction, Form 4, beneficial ownership, vesting